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Classically, the diagnosis of adenomyosis has only been possible on a hysterectomy specimen, usually in women in their late fourth
and ﬁfth decades, and, therefore, evaluating any relationship with infertility was simply not possible. As a consequence, to this
day, no epidemiologic data exists linking adenomyosis to a state of subfertility. Today, new imaging techniques have enabled a
noninvasive diagnosis at a much earlier time and a number of single-case or small series reports have appeared showing that
medical, surgical, or combined treatment can restore fertility in women with adenomyosis, an indirect proof of an association.
At the functional level, several anomalies found in the so-called junctional zone, or inner myometrium, in adenomyosis patients
have been shown to be associated with poor reproductive performance, mainly through perturbed uterine peristalsis. Additional
evidence for an association comes from experimental data: in baboons, adenomyosis is associated with lifelong primary infertility,
as well as to endometriosis. Finally, indirect proof comes from studies of the eutopic and ectopic endometrium in women with
adenomyosisprovingtheexistenceofanalteredendometrialfunctionandreceptivity.Inconclusion,suﬃcientindirectproofexists
linking adenomyosis to infertility to warrant systematic clinical studies.
1.Introduction
Adenomyosis has been deﬁned as the “benign invasion of
endometrium into the myometrium, producing a diﬀusely
enlarged uterus which microscopically exhibits ectopic non-
neoplastic endometrial glands and stroma surrounded by a
hypertrophic and hyperplastic myometrium” [1]. Two sepa-
rate pathogenetic theories have been advanced to explain its
formation: an origin from the invagination of the deepest
portion of the endometrial mucosa between bundles of
smooth muscle ﬁbres of the myometrium, or along the in-
tramyometrial lymphatic system; a metaplastic process initi-
ating from ectopic intramyometrial endometrial tissue pro-
duced de novo [2].
It has long been suspected that the presence of adeno-
myosis provokes a condition of subfertility. Unfortunately,
unlike endometriosis where an association with infertility
hasbeenallbutproven[3],classicallythediagnosisofadeno-
myosis has been, until recently, carried out on hysterectomy
specimens and in women in their late thirties and forties.
This reality made it impossible to evaluate its eﬀects on
fertility [4].
Nonetheless, as early as 1988, Honor´ e et al. [5] published
three cases of “adenomyoma,” a rare, localised form of ad-
enomyosis [6], in young infertile women in whom surgery
was carried out because of a diagnosis of leiomyoma. Based
on this ﬁnding, they advocated early diagnosis and surgical
intervention.
The situation changed some 25 years ago, with the
identiﬁcation through magnetic resonance (MR) imaging
of a new functional uterine zone: the junction between the
endometrium and the inner myometrium, named uterine
junctional zone (JZ), measuring, in healthy young women,
5mm in thickness or less [7]; this zone is clearly thickened
in the presence of adenomyosis [8]. This was followed by
attempts at identifying both the JZ and the presence of
adenomyosis through ultrasonography [9], a technique now
validated using a coronal section of the uterus obtained by
three-dimensional trans vaginal sonography (TVS) [10].2 Obstetrics and Gynecology International
Today both techniques can be utilised for an accurate
evaluation and measurement of the JZ and of its alterations
in the presence of adenomyosis, since they have good sensi-
tivity and speciﬁcity. With regard to TVS, in a histologically
controlled study Exacoustos et al. [10] have shown that the
presenceofmyometrialcystsrepresentsthemostspeciﬁc2D-
TVS feature for a correct diagnosis of adenomyosis, with a
speciﬁcity of 98% and an accuracy of 78%. In their study, the
most sensitive feature was the presence of a heterogeneous
myometrium (sensitivity: 88%; accuracy: 75%). For 3D-
TVS the best sensitivity is given by a JZ diﬀerence in
thickness ≥4mm and JZ inﬁltration and distortion (88%),
with an accuracy of 85% and 82%, respectively. Exacoustos
et al. concluded: “for 2D-TVS and 3D-TVS, respectively, the
overall accuracy for diagnosis of adenomyosis was 83% and
89%, the sensitivity was 75% and 91%, the speciﬁcity was
90%and88%,thepositivepredictivevaluewas86%and85%
and the negative predictive value was 82% and 92%.”
According to Dueholm et al. [11], MR imaging is
superior to TVS for the diagnosis of adenomyosis, having
equal sensitivity but a higher speciﬁcity (sensitivity: MR
0.70 (0.46–0.87) and TVS 0.68 (0.44–0.86) (P = .66);
speciﬁcity: MR 0.86 (0.76–0.93) and TVS 0.65 (0.50–0.77)
(P = .03)). They point out that MR diagnostic accuracy
improves when excluding uteri >400mL and conclude that
the combination of MRI and TVS produces the highest
level of accuracy for exclusion of adenomyosis. In addition,
measurement of the diﬀerence in junctional zone thickness
may optimize the MR diagnosis. In the study by Dueholm
et al., the combination of MRI and TVS was most sensitive
(0.89 (0.64–0.98)), but produced the lowest speciﬁcity (0.60
(0.44–0.73)). Exclusion of uteri >400mL from the analysis
improved the diagnostic precision of MRI, but not that of
TVS. The diagnostic accuracy at MRI was also improved by
calculating the maximum diﬀerence between the thinnest
and thickest junctional zone (JZdif) (i.e., > or = 5–7mm).
The availability of noninvasive, imaging techniques
enabling a preoperatory diagnosis of adenomyosis [12–15],
have not only revolutionised treatment [16], they have
renewedinterestbythescientiﬁccommunityonanotherwise
neglected condition, creating a ﬂurry of research activities
leading also to improved knowledge of the relationship
between adenomyosis and endometriosis [17].
2. The Uterine JunctionalZone
The inner myometrium, or junctional zone myometrium,
also called “archimetra” [18] possesses a speciﬁc character-
istic that distinguishes it from other similar junctions in
the human body: it lacks a recognisable protective layer or
membrane, forcing endometrial glands into direct contact
with the myometrium. MR, T2-weighted images of the
uterus, display in healthy women of reproductive age three
distinctlayers[14]:(1)theendometrialmucosaorinnermost
stratum, providing a signal of high intensity; (2) the already
mentioned, intermediate area immediately subendometrial,
giving a signal of low intensity and named junctional zone
myometrium; (3) an outer zone extending all the way to the
serosal layer, or outer myometrium, with a medium-signal
intensity.
Recently, a classiﬁcation for adenomyosis has been
proposed by Gordts et al. [6]: simple JZ hyperplasia (zone
thickness ≥8mm but <12mm on T2-weighted images, in
women aged 35 years or less); partial or diﬀuse adenomyosis
(thickness ≥12mm; high-signal intensity myometrial foci;
involvement of the outer myometrium: <1/3, <2/3, > 2/3),
adenomyoma (myometrial mass with indistinct margins
of primarily low-signal intensity on all MR sequences).
Unfortunately, this classiﬁcation has never been debated or
submitted to a consensus meeting and, therefore, remains to
be validated.
Research carried out over the last two decades has now
provided proper information on the nature and functions of
the JZ. It has been shown that the zone undergoes cyclical
changes in its thickness that mimic that of the endometrium
and are characterised by maximum growth between days
8a n d1 6[ 12], making it a hormone-dependent structure
that governs uterine peristalsis outside pregnancy. Dur-
ing postmenopause, under suppression of ovarian activity
with hormonal contraception, or following administration
of gonadotropin releasing-hormone analogues (GnRH-A),
the myometrial layers become indistinct on MR imaging,
although use of hormone replacement therapy results in the
reappearance of the typical zonal anatomy [19].
Transabdominal ultrasound imaging has now shown
the presence in the myometrium of distinct contraction
waves; this peristaltic activity originates exclusively from
the junctional zone, while the outer myometrium remains
quiescent. During the follicular and periovulatory phases,
contraction waves have a cervicofundal orientation and their
amplitude and frequency increase signiﬁcantly towards the
time of ovulation [20]. These waves are probably implicated
in many aspects of the physiological reproductive process:
endometrial diﬀerentiation [21], menstruation [22], sperm
transport [23], and implantation [24]. Myometrial contrac-
tions have the ability to transport and preferentially direct
microspheres placed in the vagina to mimic spermatozoa,
towards the peritoneal opening of the tubes on the side
of the dominant follicle [25]. During the luteal phase,
uterine contractility decreases and myometrial contraction
waves become short and asymmetrical, often running in
opposing directions. This reduced activity may help the
implantation process that, classically, takes place near the
fundus and possibly facilitates local supply of nutrients and
oxygen. In addition, in humans, interstitial and intravascular
trophoblast invasion goes beyond the endometrium and
involves the junctional zone, but not the outer myometrium
[26]. Finally, 7 days after ovulation, at a time coinciding
with embryo implantation there is a focal disruption of the
junctional zone signal intensity [24].
Given the fact that the presence of adenomyosis involves
alterations of the myometrium, as well as of the ZJ, a critical
area for successful reproduction, it seems reasonable to hy-
pothesisetheexistenceofarelationshipwithsubfertility[27].
Evidence is also available of a close relationship between the
occurrenceof adenomyosis and the structuraland functional
defects in the eutopic endometrium and the myometrialObstetrics and Gynecology International 3
uterine JZ. These abnormalities in turn may cause implan-
tation failure and infertility [28].
3. Evidence Linking Adenomyosis to Infertility
As already stressed, the advent of high resolution imaging
techniques has completely revolutionised our ability to
identify the presence of milder forms of adenomyosis and,
therefore, to explore a possible link with infertility.
Although no epidemiologic evidence exists, indirect data
are available and provide a good case for an association
between adenomyosis and infertility. Already ﬁfteen years
ago, de Souza et al. [27] reported an incidence of 54%
myometrial JZ hyperplasia (a clear sign of adenomyosis) in
subfertile patients complaining of menorrhagia or dysmen-
orrhoea. The mean age of these women was 34 years and
some 70% of them were nulliparae. Several studies have
conﬁrmed the early work of de Souza: the disease can be
present even in young women and be associated with both
pelvic endometriosis and infertility and therefore may well
represent a contributing factor [29–32]. This is more so
since today, in western countries, an increasing number of
womendelaytheirﬁrstpregnancyuntiltheirlate30sorearly
40s and, as a consequence, more women are found to have
adenomyosis in fertility clinics during their diagnostic work-
up [33].
Some evidence of an association can also be derived from
reports of infertile women achieving pregnancy after being
treated for adenomyosis. The ﬁrst agents utilised for this
purpose were GnRH-A [34] and several case reports or small
series have been published with the analogue given alone, or
in combination with surgery. In this connection, it has been
found that, in IVF cycles, MR evaluation of junctional zone
thickness is the best predictive factor of implantation failure
[35], in the sense that an increase in JZ diameter is inversely
correlated to the implantation rate. In fact, a thickened JZ is
an independent factor for embryo implantation failure, and
it is especially independent from embryo quality, infertility
subtype,orpatientsage[36].Thisobservationhasimportant
clinical implications: in the presence of JZ thicker than
10mm it becomes necessary to discuss with the patient
whethertoproceedimmediatelywithIVF,ortopostponethe
procedure and carry out treatment with a GnRH analogue,
a procedure that has the potential to reduce JZ thickness as
assessed by successive MR [37]. Early results [38]s e e mt o
conﬁrm an improvement of IVF results after this kind of
therapy. In addition, prolonged pretreatment with GnRH-A
before IVF has been reported to improve clinical pregnancy
rates in infertile women with endometriosis [39]. Although,
no data are available on women with adenomyosis, it seems
reasonable to infer that also in this case pre-treatment may
be beneﬁcial.
Analogues can oﬀer many advantages as a treatment
for adenomyosis-associated infertility, over and above the
hypooestrogenic state they produce: therapy with GnRH-
A decreases expression of aromatase cytochrome P450 in
the eutopic endometrium of women with adenomyosis and
endometriosis [40] and it is well known that this enzyme is
overexpressed in patients with these conditions. In women
with adenomyosis, GnRH-A can suppress the generation of
peroxynitrite,acompoundknowntocausetissueinjury[41].
Several reports exist on the use of GnRH-A in the
treatment of adenomyosis-associated infertility; the ﬁrst
case, ending in miscarriage, dates back to 1993 [42]; this
was followed in 1994 by the ﬁrst report of a successful
term pregnancy [43]. Reports of small series of successful
combined (GnRH-A plus surgery) treatment in women with
adenomyosis seeking pregnancy have also appeared [44–
47]. Additional evidence of a linkage between adenomyosis
and infertility comes from a small Japanese study using an
intrauterine system releasing danazol, in which three out
of four infertile women conceived after removal [48]. A
second, more recent option is oﬀered by the levonorgestrel-
releasing IUS, known as Mirena, although—so far—it has
been only utilised for the relief of symptoms associated
with adenomyosis [49, 50]. Finally, surgery has also been
utilisedtorestorefertilityinwomenwithadenomyosis;anew
conservative surgical technique called “adenomyomectomy”
seems to oﬀer good results (a pregnancy rate of around 50%)
[51].
On a diﬀerent front, there is good experimental evidence
linkingadenomyosistoinfertility.Indeed,inbaboonsadeno-
myosis is not only strongly associated with lifelong primary
infertility, but also statistically signiﬁcantly associated to
endometriosis [52]. Finally, it has been known for some
timesthatasubfamilyofhomeoboxgenesnamedAbdominal
B( AbdB), are involved in the developing urogenital system
in vertebrates. Satokata et al. [53]h a v em u t a t e do n eo ft h e
AbdB genes named Hoxa10 in mice and observed that female
homozygotes ovulate normally, but—if pregnancy occurs—
in the great majority of animals it ends with the death of all
embryos, and abortion occurs at the time when the Hoxa10
gene should be expressed (2.5 to 3.5 days after coitus). This
means that proper expression of the maternal Hoxa10 gene
is necessary to maintain viability of the preimplantation
embryo, and, recently, it has been proven that in women
withadenomyosistheexpressionofHoxa10 geneisdecreased
duringthesecretoryphaseofthecycle,apossibleexplanation
for the observed lower implantation rate in women with
adenomyosis [54].
4. Possible MechanismsInvolvedin
Adenomyosis-Associated Infertility
The above-mentioned data not only support the hypothesis
thatadenomyosismaybeassociatedwithinfertility;theyalso
provide a number of clues as to which mechanisms may
be involved. Indeed, structural and functional defects of the
uterine JZ, as well as the existence of several dysregulated
proteins can cause implantation failure. In addition, a
number of other conditions can, in theory at least, impair
fertility: the presence of abnormal levels of intrauterine free
radicals; an aberrant endometrial development throughout
the menstrual cycle, possibly as a consequence of an abnor-
mal local steroid metabolism; a lack of expression of some
of the “implantation markers”; an altered function of genes
essential for embryonic development.4 Obstetrics and Gynecology International
4.1. Dysregulation of Myometrial Architecture and Function.
An interesting comparative analysis of protein expression in
adenomyotic tissue and in normal myometrium has been
conducted by Liu et al. [55], who found that in women with
adenomyosis there are 12 dysregulated protein spots and
were able to identify 10 of them by mass spectrometry. In
subjects with adenomyosis myocytes exhibit cellular hyper-
trophy, to the point that smooth muscle cells become ultra-
structurally diﬀerent from smooth muscle cells of normal
uteri. The JZ shows cellular and nuclear hypertrophy,
abnormal nuclear and mitochondrial shape, and a number
of other abnormalities that may cause a disturbance in the
normal calcium cycling in the aﬀected myocytes, with a
subsequent loss of normal rhythmic contractions [56].
Although it is too early to conclude that these phenomena
may be implicated in creating a subfertility condition, it has
been shown that adenomyosis causes an impairment of the
rapid, sustained, and accurately directed sperm transport
in the uterus consequent to the destruction of the normal
architecture of the JZ myometrium [18]. These patients also
show a reduced uterotubal transport capacity that progres-
sively decreases with increasing severity of the disease; also,
a major disruption of uterotubal transport has been detected
using radionuclides in women with diﬀuse adenomyosis and
primary infertility [57, 58]. Finally, adenomyosis is associ-
ated to a loss of nerve ﬁbres at the endometrial-myometrial
interface [59].
Although no deﬁnite explanation exists for the role of a
thickened JZ in reducing implantation rates, the hypothesis
has been brought forward that, under abnormal hormonal
inﬂuence,ectopicendometrial glandscantriggeran“inﬂam-
matory” reaction. This would be mediated by cytokines,
prostaglandins, or other still unspeciﬁed factors and would
determine smooth muscle proliferation that, in turn, would
alter uterine contractions [60].
4.2.AlteredEndometrialFunctionandReceptivity. Withinthe
endometrium itself, the presence of abnormal levels of free
radical concentration represents a possible cause for infer-
tility in adenomyosis patients. This is because a disruption of
the balance between reactive oxygen species and antioxidants
produces oxidative stress and an excessive free radical
environment. In turn, this can damage fertilized eggs and
inhibit embryo development and pregnancy, and Noda et
al. [61] have shown that low concentrations of free radicals
are necessary to create an appropriate environment for early
embryonic development. In the presence of abnormal levels
of free radicals the embryo may be attacked by activated
macrophages or T cells, or be exposed to an excess of nitric
oxide, which may result in early miscarriage [62]. A number
of investigations have focused on enzymes producing or
eliminating free radicals: two of them are particularly inter-
esting in this context: xanthine oxidase (XO) that produces
superoxide and superoxide dismutase (SOD) that eliminates
it, while simultaneously producing hydroxyl radicals, that,
in turn, can be eliminated by glutathione peroxidase (GPx).
It has been shown that in women with adenomyosis, nitric
oxide synthase (NOS), XO, SOD, and catalase levels do not
ﬂ u c t u a t ea n da r eo v e re x p r e s s e d[ 63, 64]; interestingly, as
already mentioned, administration of GnRH-A suppresses
the expression of both eNOS and iNOS and the formation
of peroxynitrite in adenomyosis [40].
Alteredoxidative stressequilibriumisnottheonlymech-
anism through which a uterine environment hostile to the
developing embryo can be produced in women with ade-
nomyosis. Another important abnormality that may lead to
an impairment of implantation has now been identiﬁed: in
women with adenomyosis there is an aberrant endometrial
development throughout the proliferative phase, and this
may lead to abnormalities of the secretory phase. This
seems due to altered endometrial vascularisation, an increase
in regulatory factors involved in the endometrial vascular
proliferation and changes in endometrial molecular markers
of inﬂammation [65, 66]. Indeed, in subjects with adeno-
myosis, in both eutopic and ectopic endometria there is
a signiﬁcantly greater activity of the vascular endothelial
growth factor (VEGF) of microvessel density [67] and of the
hypoxia-inducible factor-1alpha [68]. Furthermore, a series
of anomalies have been found in the secretion of inter-
leukins in both eutopic and ectopic endometria of subjects
with adenomyosis, again leading to a disruption of early
events related to implantation. These anomalies involve an
improper secretion of interleukins-6 [69], -8 [65], and -10
[70]. In conclusion, in women with adenomyosis an abnor-
mal inﬂammatory response seems to exist and impair
nidation.
There is a third mechanism through which an altered
endometrium can lead to implantation failure: an abnormal
intraendometrium metabolism. Since in adenomyosis IL-6
is over expressed [69], this could lead to increased oestrogen
receptor expression and, indeed, the expression of the dif-
ferent isoforms of oestrogen receptor alpha (ER-α)a n db e t a
(ER-β) and progesterone receptor A (PR-A) and B (PR-B)
are diﬀerentially modulated in uteri with adenomyosis com-
pared with controls [71]. In addition, in the endometrium
of subjects with adenomyosis there is over expression of
cytochrome P450 [72]; this phenomenon increases local
oestrogen production [73], and it has been shown that
an over expression of endometrial aromatase signiﬁcantly
lowers clinical pregnancy rates (with similar numbers of
retrieved oocytes and replaced embryos with respect to
controls) [74]. In these women there is also a defect in
progesterone receptors and loss of their action [75]; this
altered balance between oestrogen and progesterone results
in the persistence of ER-α, given that downregulation of this
receptor is one of the primary functions of progesterone.
The overexpression of ER-α in midsecretory phase reduces
the secretion of beta 3 integrins, negatively regulated by
oestrogens, thereby altering uterine receptivity [76]. The
observed reduction in PR expression may even explain
the poor response to progestational agents in women with
adenomyosis [77].
In adenomyotic foci, ER-α staining does not vary during
the menstrual cycle in either glands or stroma; conversely,
there are no cyclical changes in its expression in the inner-
most or outer myometrium. Furthermore, ER-β expression
in the proliferative phase is statistically signiﬁcantly higher
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controls. Expression is similarly higher in the basalis, the
stroma, the JZ, and outer myometrium, compared with
control tissue where expression is weak and shows no
statistically signiﬁcant variation with the phase of the cycle
[71]. The higher ER-β expression in the myometrium of
adenomyotic uteri might thus contribute to the presence of
the classically described myometrial hyperplasia [55].
A fourth mechanism that can lead to implantation
failure is a lack of expression of some of the molecules,
labelled “implantation markers,” that are expressed by the
endometrium and are required for the successful interaction
between embryo and endometrium. In 2006, Yen et al.
[78] have reported that during the implantation window,
some of these markers are decreased in the endometrium of
women with adenomyosis, suggesting that this may be one
of the molecular mechanisms associated with a decreased
implantation rate.
In particular, it has been demonstrated that the so-
called Leukemia Inhibitory Factor (LIF) is associated with
endometrial receptivity and is lower in women with infer-
tility compared with healthy controls [79]. It has also been
shown that LIF expression is decreased in the endometrium
in women with adenomyosis during midsecretory phase
and, when these women have a history of infertility, they
show signiﬁcantly lower LIF levels in uterine ﬂushing ﬂuid,
c o m p a r e dw i t hf e r t i l ec o n t r o l s[ 80].
One of them, the α-4, β-3 integrin appears on the surface
of epithelial cells of both embryo and endometrium and on
maternal surfaces around cycle day 19 to 20 and continues
to be expressed during pregnancy [81]. Although it is not
known whether its expression is modiﬁed in women with
adenomyosis, it has been shown that integrin is missing
in a subset of women with unexplained infertility and
endometriosis [82]. Information on this and several other
proteinssuchasglycodelin,osteopontin,andvitronectinthat
arebelievedtomediatetrophoblast-endometrialinteractions
during implantation and are downregulated in women
with endometriosis [83, 84], is still lacking in the case
of adenomyosis, but it can at least be speculated that a
mechanism of this kind may also be involved.
A ﬁfth important factor that may be involved in creating
an impairment of implantation in women with adenomyosis
is the already mentioned altered function of the HoxaA10
gene. As stated above, this gene is part of a homeobox-
containing transcription factors essential for embryonic
development and proper adult endometrial growth during
the menstrual cycle [85] and in women with adenomyosis
expression its is signiﬁcantly lower during the midsecretory
phase compared with fertile controls [54].
5. Conclusions
At present it is impossible to show conclusively that ade-
nomyosis can lead to subfertility or infertility because no
epidemiologicstudieshaveeverbeencarriedout.Atthesame
time,itishopedthattheintroductionofMRand,evenmore,
that of the more readily available 3D-TVS will facilitate early
diagnosis and help collecting missing data. Notwithstanding
this unsatisfactory situation, a careful look at molecular
pathophysiology of the disease and at preliminary clinical
results with a number of new techniques [28] can already
help clarifying the situation although, the ﬁnal answers lie
in the execution of controlled clinical investigations.
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